ArticleThe American statistician2025
Sequential monitoring using the Second Generation P-Value with Type I error controlled by monitoring frequency.
Article in The American statistician, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The Second Generation P-Value (SGPV) measures the overlap between an estimated interval and a composite hypothesis of parameter values. We develop a sequential monitoring scheme of the SGPV (SeqSGPV) to connect study design intentions with end-of-study inference anchored on scientific relevance. We build upon Freedman's "Region of Equivalence" (ROE) in specifying scientifically meaningful hypotheses called Pre-specified Regions Indicating Scientific Merit (PRISM). We compare PRISM monitoring versus monitoring alternative ROE specifications. Error rates are controlled through the PRISM's indifference zone around the point null and monitoring frequency strategies. Because the former is fixed due to scientific relevance, the latter is a targettable means for designing studies with desirable operating characters. An affirmation step to stopping rules improves frequency properties including the error rate, the risk of reversing conclusions under delayed outcomes, and bias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.